首页 > 最新文献

Journal of gastrointestinal and liver diseases : JGLD最新文献

英文 中文
Color Mapping using Ultrasound System-integrated Perfusion Software for Evaluation of Focal Liver Lesions: A Possible First Step for More Independent Reading. 利用超声系统集成灌注软件绘制彩色图谱,评估肝脏病灶:更多自主阅读的第一步。
Pub Date : 2023-12-22 DOI: 10.15403/jgld-4997
Ivor Dropco, Ulrich Kaiser, Lola Wagner, Stefan M Brunner, Hans Jürgen Schlitt, Christian Stroszcynski, Friedrich Jung, Dong Yi, Wolfgang Herr, Ernst Michael Jung

Aims: To assess the value of using integrated parametric ultrasound software for contrast-enhanced ultrasonography (CEUS) of liver tumors.

Methods: 107 patients with liver tumors were studied. CEUS were performed to detect focal lesions. Parametric images were based on continuous CINE LOOPs, from the early-arterial phase (15 s) to the portal-venous phase (1 min) generated by perfusion software. The evaluations of the parametric images and their dignity for liver lesions were performed independently by an experienced and a less-experienced investigator. Computed tomography, magnetic resonance imaging scans or histological analysis were used as references.

Results: High parametric image quality were obtained in all patients. Among the patients, 44% lesions were benign, 56% were malignant. The experienced investigator correctly classified 46 of 47 (98%) as benign, and 60 of 60 (100%) as malignant tumors based on the parametric images. The less-experienced investigator correctly classified 39 of 47 (83%) as benign, and 49 of 60 (82%) malignant tumors, acheaving a high statistical accuracy of 98% with this type of diagnostic.

Conclusion: Parametric imaging for grading the malignant degree of tumor may be a good complement to existing ultrasound techniques and was particularly helpful for improving the assessments of the less-experienced examiner.

目的:评估在肝脏肿瘤对比增强超声造影(CEUS)中使用集成参数超声软件的价值。进行CEUS检查以检测病灶。参数图像基于灌注软件生成的从早期动脉期(15 秒)到门-静脉期(1 分钟)的连续 CINE LOOP。一名经验丰富的研究人员和一名经验较少的研究人员分别独立评估参数图像及其对肝脏病变的重要性。计算机断层扫描、磁共振成像扫描或组织学分析作为参考:所有患者均获得了高参数图像质量。其中,44%为良性病变,56%为恶性病变。根据参数图像,经验丰富的研究人员将 47 例中的 46 例(98%)正确分类为良性肿瘤,将 60 例中的 60 例(100%)正确分类为恶性肿瘤。经验较少的研究人员则将 47 例中的 39 例(83%)正确划分为良性肿瘤,将 60 例中的 49 例(82%)正确划分为恶性肿瘤,此类诊断的统计准确率高达 98%:参数成像对肿瘤恶性程度的分级可能是对现有超声技术的良好补充,尤其有助于提高经验不足的检查人员的评估能力。
{"title":"Color Mapping using Ultrasound System-integrated Perfusion Software for Evaluation of Focal Liver Lesions: A Possible First Step for More Independent Reading.","authors":"Ivor Dropco, Ulrich Kaiser, Lola Wagner, Stefan M Brunner, Hans Jürgen Schlitt, Christian Stroszcynski, Friedrich Jung, Dong Yi, Wolfgang Herr, Ernst Michael Jung","doi":"10.15403/jgld-4997","DOIUrl":"10.15403/jgld-4997","url":null,"abstract":"<p><strong>Aims: </strong>To assess the value of using integrated parametric ultrasound software for contrast-enhanced ultrasonography (CEUS) of liver tumors.</p><p><strong>Methods: </strong>107 patients with liver tumors were studied. CEUS were performed to detect focal lesions. Parametric images were based on continuous CINE LOOPs, from the early-arterial phase (15 s) to the portal-venous phase (1 min) generated by perfusion software. The evaluations of the parametric images and their dignity for liver lesions were performed independently by an experienced and a less-experienced investigator. Computed tomography, magnetic resonance imaging scans or histological analysis were used as references.</p><p><strong>Results: </strong>High parametric image quality were obtained in all patients. Among the patients, 44% lesions were benign, 56% were malignant. The experienced investigator correctly classified 46 of 47 (98%) as benign, and 60 of 60 (100%) as malignant tumors based on the parametric images. The less-experienced investigator correctly classified 39 of 47 (83%) as benign, and 49 of 60 (82%) malignant tumors, acheaving a high statistical accuracy of 98% with this type of diagnostic.</p><p><strong>Conclusion: </strong>Parametric imaging for grading the malignant degree of tumor may be a good complement to existing ultrasound techniques and was particularly helpful for improving the assessments of the less-experienced examiner.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"32 4","pages":"479-487"},"PeriodicalIF":0.0,"publicationDate":"2023-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139041147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply. 答复
Pub Date : 2023-12-22 DOI: 10.15403/jgld-5411
Francesco Di Mario
{"title":"Reply.","authors":"Francesco Di Mario","doi":"10.15403/jgld-5411","DOIUrl":"10.15403/jgld-5411","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"32 4","pages":"559-560"},"PeriodicalIF":0.0,"publicationDate":"2023-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139041149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Childlessness in Patients with Inflammatory Bowel Disease - Data from the Prospective Multi-center Swiss IBD Cohort Study. 炎症性肠病患者的无子女情况--来自前瞻性多中心瑞士 IBD 队列研究的数据。
Pub Date : 2023-12-22 DOI: 10.15403/jgld-5132
Michael Christian Sulz, Michael Doulberis, Nicolas Fournier, Luc Biedermann, Jonas Zeitz, Benjamin Misselwitz, Bruno Imthurn, Gerhard Rogler

Background and aims: Childlessness and infertility represent a frequent and important issue in inflammatory bowel disease (IBD) patients. Nevertheless, until now epidemiological data remains scarce. Therefore, main objectives of this study were to evaluate the rate of childlessness and the cumulative probability of reproduction in female and male IBD patients within the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS), a large prospective multicenter nationwide cohort.

Methods: Prospectively collected data of SIBDCS was used, comprising more than 3,300 patients with Crohn's disease (CD) and ulcerative colitis (UC). We analyzed the following groups of patients: 1) female IBD patients aged ≥40 years and diagnosed before age of 30 years with at least one follow-up, 2) female IBD patients who reported actively trying to conceive, with IBD diagnosed <35 years and with age at enrolment <45 years (longitudinal observation), with at least one follow-up, and 3) childless males who actively tried to conceive.

Results: A total of 1,412 female patients from the SIBDCS [843 CD, 539 UC, 30 indeterminate colitis (IC)] with available data were included in our analyses. Out of those 184 females (70.1% CD and 29.9 % UC) were aged ≥ 40 years and have been diagnosed with IBD before the age of 30 years. Among these, 184 women 32.1% were childless. The portion of childless females (36.4%) was significantly higher in CD vs. UC (36.4% vs. 21.8%; p=0.026), equaling a relative risk of childlessness of 1.7 in CD vs. UC. and higher than in the Swiss general population (21%). The mean number of children per female patient was 1.32 (median 1, min 0, max 6), per female with CD 1.12 (median 1, min 0, max 4), per female with UC/IC 1.78 (median 2, min 0, max 6; P=0.001). The longitudinal analysis of female IBD patients trying to conceive revealed that one out of two women neither were pregnant nor had born a child five years after first trying to conceive.

Conclusions: The rate of childlessness in females with CD is higher compared to the general Swiss population, whereas it is similar in women with UC. Moreover, the mean number of children is lower in CD than in UC. Females with CD remain more often childless compared to their UC counterparts. Although the exact underlying mechanisms are largely unknown, this discrepancy should alert healthcare professionals treating CD patients to actively address this topic.

背景和目的:无子女和不育是炎症性肠病(IBD)患者经常遇到的一个重要问题。然而,到目前为止,流行病学数据仍然很少。因此,本研究的主要目的是评估瑞士炎症性肠病队列研究(SIBDCS)这一大型前瞻性多中心全国性队列中女性和男性 IBD 患者的无子女率和累积生育概率:方法:我们使用了瑞士炎症性肠病队列研究(SIBDCS)的前瞻性数据,其中包括 3300 多名克罗恩病(CD)和溃疡性结肠炎(UC)患者。我们对以下几组患者进行了分析:1)年龄≥40 岁且在 30 岁前确诊并至少随访过一次的女性 IBD 患者;2)报告积极尝试怀孕且确诊有 IBD 的女性 IBD 患者:共有 1,412 名来自 SIBDCS 的女性患者[843 名 CD 患者、539 名 UC 患者、30 名不确定结肠炎患者 (IC)]的可用数据被纳入我们的分析。其中 184 名女性患者(70.1% 为 CD,29.9% 为 UC)的年龄≥ 40 岁,并在 30 岁之前被诊断出患有 IBD。在这 184 名女性中,32.1% 无子女。CD与UC相比,无子女女性的比例(36.4%)明显更高(36.4% vs. 21.8%;P=0.026),相当于CD与UC无子女的相对风险为1.7,高于瑞士普通人群(21%)。每位女性患者的平均子女数为 1.32 个(中位数为 1 个,最少 0 个,最多 6 个),每位 CD 女性患者的平均子女数为 1.12 个(中位数为 1 个,最少 0 个,最多 4 个),每位 UC/IC 女性患者的平均子女数为 1.78 个(中位数为 2 个,最少 0 个,最多 6 个;P=0.001)。对试图怀孕的女性 IBD 患者进行的纵向分析表明,每两名女性中就有一人在首次尝试怀孕五年后既未怀孕也未生育:结论:与瑞士普通人群相比,CD 女性患者的无子女率较高,而 UC 女性患者的无子女率与之相似。此外,CD 女性的平均子女数也低于 UC 女性。与患有 UC 的女性患者相比,患有 CD 的女性患者更经常无子女。虽然确切的内在机制尚不清楚,但这一差异应提醒治疗 CD 患者的医护人员积极应对这一问题。
{"title":"Childlessness in Patients with Inflammatory Bowel Disease - Data from the Prospective Multi-center Swiss IBD Cohort Study.","authors":"Michael Christian Sulz, Michael Doulberis, Nicolas Fournier, Luc Biedermann, Jonas Zeitz, Benjamin Misselwitz, Bruno Imthurn, Gerhard Rogler","doi":"10.15403/jgld-5132","DOIUrl":"10.15403/jgld-5132","url":null,"abstract":"<p><strong>Background and aims: </strong>Childlessness and infertility represent a frequent and important issue in inflammatory bowel disease (IBD) patients. Nevertheless, until now epidemiological data remains scarce. Therefore, main objectives of this study were to evaluate the rate of childlessness and the cumulative probability of reproduction in female and male IBD patients within the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS), a large prospective multicenter nationwide cohort.</p><p><strong>Methods: </strong>Prospectively collected data of SIBDCS was used, comprising more than 3,300 patients with Crohn's disease (CD) and ulcerative colitis (UC). We analyzed the following groups of patients: 1) female IBD patients aged ≥40 years and diagnosed before age of 30 years with at least one follow-up, 2) female IBD patients who reported actively trying to conceive, with IBD diagnosed <35 years and with age at enrolment <45 years (longitudinal observation), with at least one follow-up, and 3) childless males who actively tried to conceive.</p><p><strong>Results: </strong>A total of 1,412 female patients from the SIBDCS [843 CD, 539 UC, 30 indeterminate colitis (IC)] with available data were included in our analyses. Out of those 184 females (70.1% CD and 29.9 % UC) were aged ≥ 40 years and have been diagnosed with IBD before the age of 30 years. Among these, 184 women 32.1% were childless. The portion of childless females (36.4%) was significantly higher in CD vs. UC (36.4% vs. 21.8%; p=0.026), equaling a relative risk of childlessness of 1.7 in CD vs. UC. and higher than in the Swiss general population (21%). The mean number of children per female patient was 1.32 (median 1, min 0, max 6), per female with CD 1.12 (median 1, min 0, max 4), per female with UC/IC 1.78 (median 2, min 0, max 6; P=0.001). The longitudinal analysis of female IBD patients trying to conceive revealed that one out of two women neither were pregnant nor had born a child five years after first trying to conceive.</p><p><strong>Conclusions: </strong>The rate of childlessness in females with CD is higher compared to the general Swiss population, whereas it is similar in women with UC. Moreover, the mean number of children is lower in CD than in UC. Females with CD remain more often childless compared to their UC counterparts. Although the exact underlying mechanisms are largely unknown, this discrepancy should alert healthcare professionals treating CD patients to actively address this topic.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"32 4","pages":"460-468"},"PeriodicalIF":0.0,"publicationDate":"2023-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139041146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Accelerated dose of ustekinumab for acute severe ulcerative colitis. 加速剂量的ustekinumab治疗急性严重溃疡性结肠炎。
Pub Date : 2023-09-29 DOI: 10.15403/jgld-4825
İdris Kurt
We read with interest Affendi et al. [1] report about a patient with severe ulcerative colitis who responded to an accelerated dose of ustekinumab. We have the following comments and concerns. The patient‘s endoscopic images do not show the typical Mayo score 3 appearances of colitis. Severe ulcerative colitis is characterized by diffuse, circumferentially affected, granular mucosa with superficial ulcerations that may coalesce. Figures from the case show discrete, deep, oval ulcers. Furthermore, it almost has a cobblestone appearance, more specific to Crohn‘s disease [2]. In addition to colon involvement in Fig. 1A, the small intestinal loops (possible ileal segments) are thickened and edematous in the right lower quadrant, distant from the cecum. There is also the appearance of fat stranding. In ulcerative colitis, involvement of intestinal segments distant from the cecum is not expected, being specific to Crohn‘s disease [3]. Due to the severity of the disease, a pancolonoscopy could not be performed; therefore, disease extension was described using computed tomography. Not exceeding splenic flexure, it was interpreted as left-sided colitis. According to his medical history, 3 grams of mesalazine was started three weeks prior to his admission. Mesalazine >2.4 g/dL enteral and 1-gram topical forms are recommended by the 2017 ECCO (European Crohn‘s and Colitis Organisation) guideline for left-sided ulcerative colitis. The remission induction rate at this dose is high when compared to placebo [4]. If the patient has left-sided ulcerative colitis, we anticipate a positive response to a sufficient dose of 5-acetylsalicylic acid preparation. Finally, the histopathological findings are not mentioned in the article. Although there are no pathognomonic features specific to ulcerative colitis, the presence of granulomas (which can be found in 15-36% of mucosal biopsies) could indicate Crohn‘s disease [4, 5]. LETTERS TO THE EDITOR
{"title":"Accelerated dose of ustekinumab for acute severe ulcerative colitis.","authors":"İdris Kurt","doi":"10.15403/jgld-4825","DOIUrl":"10.15403/jgld-4825","url":null,"abstract":"We read with interest Affendi et al. [1] report about a patient with severe ulcerative colitis who responded to an accelerated dose of ustekinumab. We have the following comments and concerns. The patient‘s endoscopic images do not show the typical Mayo score 3 appearances of colitis. Severe ulcerative colitis is characterized by diffuse, circumferentially affected, granular mucosa with superficial ulcerations that may coalesce. Figures from the case show discrete, deep, oval ulcers. Furthermore, it almost has a cobblestone appearance, more specific to Crohn‘s disease [2]. In addition to colon involvement in Fig. 1A, the small intestinal loops (possible ileal segments) are thickened and edematous in the right lower quadrant, distant from the cecum. There is also the appearance of fat stranding. In ulcerative colitis, involvement of intestinal segments distant from the cecum is not expected, being specific to Crohn‘s disease [3]. Due to the severity of the disease, a pancolonoscopy could not be performed; therefore, disease extension was described using computed tomography. Not exceeding splenic flexure, it was interpreted as left-sided colitis. According to his medical history, 3 grams of mesalazine was started three weeks prior to his admission. Mesalazine >2.4 g/dL enteral and 1-gram topical forms are recommended by the 2017 ECCO (European Crohn‘s and Colitis Organisation) guideline for left-sided ulcerative colitis. The remission induction rate at this dose is high when compared to placebo [4]. If the patient has left-sided ulcerative colitis, we anticipate a positive response to a sufficient dose of 5-acetylsalicylic acid preparation. Finally, the histopathological findings are not mentioned in the article. Although there are no pathognomonic features specific to ulcerative colitis, the presence of granulomas (which can be found in 15-36% of mucosal biopsies) could indicate Crohn‘s disease [4, 5]. LETTERS TO THE EDITOR","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"32 3","pages":"411"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41151135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute liver failure: a rare presentation of an adult-onset Still's disease. 急性肝衰竭:成人斯蒂尔病的罕见表现。
Pub Date : 2023-09-29 DOI: 10.15403/jgld-5032
Aadhar Mathur, Arihant Seth, Pankaj Gangwal, Hans Raj Pahadiya, Ajay Mathur, Laxmikant Goyal
{"title":"Acute liver failure: a rare presentation of an adult-onset Still's disease.","authors":"Aadhar Mathur,&nbsp;Arihant Seth,&nbsp;Pankaj Gangwal,&nbsp;Hans Raj Pahadiya,&nbsp;Ajay Mathur,&nbsp;Laxmikant Goyal","doi":"10.15403/jgld-5032","DOIUrl":"https://doi.org/10.15403/jgld-5032","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"32 3","pages":"414-416"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41125176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply. 回复
Pub Date : 2023-09-29 DOI: 10.15403/jgld-5217
Nik Arsyad Nik Muhamad Affendi, Choon Jin Ooi, Ida Normiha Hilmi
{"title":"Reply.","authors":"Nik Arsyad Nik Muhamad Affendi,&nbsp;Choon Jin Ooi,&nbsp;Ida Normiha Hilmi","doi":"10.15403/jgld-5217","DOIUrl":"10.15403/jgld-5217","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"32 3","pages":"412-413"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41163511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Red Meat Intake and Colorectal Cancer among East-Asians: A Systematic Review and Meta-analysis of Observational Studies Performed between 2011-2021. 东非人红肉摄入量与癌症结直肠癌的关联:2011-2021年间观察研究的系统回顾和Meta-analysis。
Pub Date : 2023-09-29 DOI: 10.15403/jgld-4778
Hoi Shan Cheung, Lok Yee Lu, Wang Leong So, Ho Wai Wong, Sei Hei Wong, Chloe Miu Mak

Background and aims: Colorectal cancer has the third highest incidence and second highest mortality among all cancers worldwide. Although numerous studies investigating the associations between high red meat intake and risk of colorectal cancer have been published, the association between the intake of red meat and the risk of colorectal cancer in Asians remains unclear. We performed a systematic review and meta-analysis of cohort and case-control studies to estimate the association between red meat intake and colorectal cancer incidence rate between 2011-2021.

Method: We searched PubMed database from 1 Jan 2011 to 21 July 2021. Prospective cohort studies and nested case-control studies that reported results on the association between red meat consumption and colorectal cancer were included in the meta-analysis. The outcome of interest was the association between the intake of red meat and the risk of colorectal cancer. We performed a meta-analysis to calculate the odds ratios (OR) with 95% confidence intervals (CI).

Results: A total of 5 studies enrolling 48,158 participants were included. The results showed no significant association between red meat intake and colorectal cancer risks (OR=1.38; 95%CI: 0.98-1.93). The aspect of the corresponding funnel plot suggested the presence of significant publication bias. Egger's test confirmed the significant asymmetry of the funnel plot (t = 9.3024, p = 0.0026).

Conclusions: Contrary to many other meta-analyses, our study showed that intake of red meat was not associated with increased risk of colorectal cancer in East-Asians from China, Japan and South Korea. However, due to the limited number of included papers and the lack of confounders adjustments, our results warrant cautious interpretations.

背景与目的:癌症的发病率居世界第三,死亡率居世界第二。尽管已经发表了大量研究,调查高红肉摄入量与结直肠癌癌症风险之间的关系,但亚洲人摄入红肉与结直肠癌癌症风险之间的关联仍不清楚。我们对队列和病例对照研究进行了系统回顾和荟萃分析,以估计2011-2021年间红肉摄入量与结直肠癌癌症发病率之间的关系。方法:我们检索了2011年1月1日至2021年7月21日的PubMed数据库。荟萃分析包括前瞻性队列研究和嵌套病例对照研究,这些研究报告了红肉消费与结直肠癌癌症之间的关联结果。感兴趣的结果是红肉的摄入与结直肠癌癌症风险之间的关系。我们进行了一项荟萃分析,以计算95%置信区间(CI)的比值比(OR)。结果:共有5项研究纳入48158名参与者。结果显示,红肉摄入量与结直肠癌癌症风险之间没有显著关联(OR=1.38;95%CI:0.98-1.93)。相应的漏斗图表明存在显著的发表偏倚。Egger检验证实了漏斗图的显著不对称性(t=9.3024,p=0.0026)。结论:与许多其他荟萃分析相反,我们的研究表明,在来自中国、日本和韩国的东亚人中,红肉的摄入与结直肠癌癌症风险的增加无关。然而,由于纳入的论文数量有限,并且缺乏混杂因素调整,我们的结果值得谨慎解释。
{"title":"Association of Red Meat Intake and Colorectal Cancer among East-Asians: A Systematic Review and Meta-analysis of Observational Studies Performed between 2011-2021.","authors":"Hoi Shan Cheung,&nbsp;Lok Yee Lu,&nbsp;Wang Leong So,&nbsp;Ho Wai Wong,&nbsp;Sei Hei Wong,&nbsp;Chloe Miu Mak","doi":"10.15403/jgld-4778","DOIUrl":"https://doi.org/10.15403/jgld-4778","url":null,"abstract":"<p><strong>Background and aims: </strong>Colorectal cancer has the third highest incidence and second highest mortality among all cancers worldwide. Although numerous studies investigating the associations between high red meat intake and risk of colorectal cancer have been published, the association between the intake of red meat and the risk of colorectal cancer in Asians remains unclear. We performed a systematic review and meta-analysis of cohort and case-control studies to estimate the association between red meat intake and colorectal cancer incidence rate between 2011-2021.</p><p><strong>Method: </strong>We searched PubMed database from 1 Jan 2011 to 21 July 2021. Prospective cohort studies and nested case-control studies that reported results on the association between red meat consumption and colorectal cancer were included in the meta-analysis. The outcome of interest was the association between the intake of red meat and the risk of colorectal cancer. We performed a meta-analysis to calculate the odds ratios (OR) with 95% confidence intervals (CI).</p><p><strong>Results: </strong>A total of 5 studies enrolling 48,158 participants were included. The results showed no significant association between red meat intake and colorectal cancer risks (OR=1.38; 95%CI: 0.98-1.93). The aspect of the corresponding funnel plot suggested the presence of significant publication bias. Egger's test confirmed the significant asymmetry of the funnel plot (t = 9.3024, p = 0.0026).</p><p><strong>Conclusions: </strong>Contrary to many other meta-analyses, our study showed that intake of red meat was not associated with increased risk of colorectal cancer in East-Asians from China, Japan and South Korea. However, due to the limited number of included papers and the lack of confounders adjustments, our results warrant cautious interpretations.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"32 3","pages":"377-383"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41163288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bezafibrate severe late onset drug-induced liver injury in primary biliary cholangitis: case report. 贝扎贝特治疗原发性胆汁性胆管炎的严重迟发性药物性肝损伤:病例报告。
Pub Date : 2023-09-29 DOI: 10.15403/jgld-5023
Mateus Jorge Nardelli, Laís Rodrigues Maffia, Fernanda Alves Gelape, Guilherme Grossi Lopes Cançado, Claudia Alves Couto
{"title":"Bezafibrate severe late onset drug-induced liver injury in primary biliary cholangitis: case report.","authors":"Mateus Jorge Nardelli,&nbsp;Laís Rodrigues Maffia,&nbsp;Fernanda Alves Gelape,&nbsp;Guilherme Grossi Lopes Cançado,&nbsp;Claudia Alves Couto","doi":"10.15403/jgld-5023","DOIUrl":"https://doi.org/10.15403/jgld-5023","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"32 3","pages":"413-414"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41169600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Sacral Nerve Stimulation in Non-constipated Irritable Bowel Syndrome Patients: A Systematic Review. 骶神经刺激对非便秘型肠易激综合征患者的疗效:系统评价。
Pub Date : 2023-09-29 DOI: 10.15403/jgld-4801
Ana Maria Garcia-Cabrera, Fernando De la Portilla, Rosa María Jiménez-Rodríguez, Jorge Manuel Vázquez-Monchul, María Luisa Reyes-Díaz, Irene María Ramallo-Solís, José Pintor-Tortolero, Sandra Dios-Barbeito, Francisco Javier Padillo-Ruiz

Background and aims: Irritable bowel syndrome (IBS) is a prevalent disorder with a complex and heterogeneous physiopathology, including a dysregulation of gut-brain axis. Treatment for IBS is targeted to the predominant symptom and requires a multidisciplinary approach. This review aims to evaluate the efficacy and safety of sacral nerve stimulation in non-constipated IBS patients Methods: A literature search was carried out on MEDLINE, The Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science databases for all relevant articles. Quality of included papers was assessed using standardized guidelines Results: Of 129 initial citations, 7 articles met our predefined inclusion criteria, including five randomized trials, a pilot study and a descriptive follow-up study. Five of 7 studies reported a positive effect of sacral nerve stimulation on symptoms and quality of life improvement in non-constipated IBS patients. No study reported serious adverse events.

Conclusions: Despite initial promising results of sacral nerve stimulation in non-constipated IBS patients, studies with larger sample sizes and longer follow-up are required.

背景和目的:肠易激综合征(IBS)是一种常见的疾病,具有复杂和异质的病理生理学,包括肠脑轴失调。IBS的治疗针对主要症状,需要多学科的方法。本综述旨在评估骶神经刺激治疗非便秘型肠易激综合征患者的有效性和安全性。方法:在MEDLINE、Cochrane对照试验中央登记册(Central)和Web of Science数据库中检索所有相关文章。纳入论文的质量使用标准化指南进行评估结果:在129篇首次引用中,有7篇文章符合我们预定义的纳入标准,包括5项随机试验、一项试点研究和一项描述性随访研究。7项研究中有5项报告了骶神经刺激对非便秘IBS患者症状和生活质量改善的积极影响。没有研究报告严重不良事件。结论:尽管骶神经刺激治疗非便秘型肠易激综合征患者的初步结果很有希望,但仍需要更大样本量和更长随访时间的研究。
{"title":"Efficacy of Sacral Nerve Stimulation in Non-constipated Irritable Bowel Syndrome Patients: A Systematic Review.","authors":"Ana Maria Garcia-Cabrera,&nbsp;Fernando De la Portilla,&nbsp;Rosa María Jiménez-Rodríguez,&nbsp;Jorge Manuel Vázquez-Monchul,&nbsp;María Luisa Reyes-Díaz,&nbsp;Irene María Ramallo-Solís,&nbsp;José Pintor-Tortolero,&nbsp;Sandra Dios-Barbeito,&nbsp;Francisco Javier Padillo-Ruiz","doi":"10.15403/jgld-4801","DOIUrl":"10.15403/jgld-4801","url":null,"abstract":"<p><strong>Background and aims: </strong>Irritable bowel syndrome (IBS) is a prevalent disorder with a complex and heterogeneous physiopathology, including a dysregulation of gut-brain axis. Treatment for IBS is targeted to the predominant symptom and requires a multidisciplinary approach. This review aims to evaluate the efficacy and safety of sacral nerve stimulation in non-constipated IBS patients Methods: A literature search was carried out on MEDLINE, The Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science databases for all relevant articles. Quality of included papers was assessed using standardized guidelines Results: Of 129 initial citations, 7 articles met our predefined inclusion criteria, including five randomized trials, a pilot study and a descriptive follow-up study. Five of 7 studies reported a positive effect of sacral nerve stimulation on symptoms and quality of life improvement in non-constipated IBS patients. No study reported serious adverse events.</p><p><strong>Conclusions: </strong>Despite initial promising results of sacral nerve stimulation in non-constipated IBS patients, studies with larger sample sizes and longer follow-up are required.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"32 3","pages":"384-392"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41169627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of COVID-19 Pandemic on Hepatocellular Carcinoma Diagnosis: Results from a Single Turkey Center Study. 新冠肺炎大流行对肝癌诊断的影响:土耳其单一中心研究结果。
Pub Date : 2023-09-29 DOI: 10.15403/jgld-4821
Gülden Bilican, Seçkin Özgül, Nergiz Ekmen, Kenan Moral, Harun Küçük, Serkan Dumanlı, Azer Abiyev, Tarkan Karakan, Murat Kekilli

Background and aims: Currently malignancies of the liver are the sixth most frequently diagnosed cancers worldwide. The admission of patients to hospitals decreased due to the restriction of the Coronavirus disease 2019 (COVİD-19) pandemic, especially patients suspected with cancer were delayed in their diagnosis and treatment. With this study, we aimed to investigate whether the Covid-19 pandemic caused a decrease in the number of hepatocellular cancers (HCC) or a delay in its diagnosis.

Methods: The study, which included newly diagnosed HCC patients, was conducted as a retrospective cross sectional study, in a single Turkey medical center. The patients were divided into pre-COVID-19 and post- COVID-19 two-year periods and compared in terms of tumor size, biochemical parameters, clinical and demographic features.

Results: A total of 63 HCC patients, 46 (73%) patients before the COVID-19 pandemic and 17 (27%) patients diagnosed during the COVID-19 pandemic were included. Maximum diameter of lesions and serum alpha- fetoprotein levels showed a statistically significant difference between the groups. Maximum tumor size in the pre-COVID-19 period was 4.58±3.77 mm, while in the COVID-19 period was 7.42±6.88 mm, the difference between two groups being statistically significant (p<0.05). HCC in the pre-COVID-19 period were detected mostly at Barcelona Clinic for Liver Cancer (BCLC) stage A (45.7%, n=21), while in the COVID-19 period most of HCC were detected at stage B (35.3%, n=6).

Conclusions: The COVID-19 pandemic limited the access of patients to screening programs for HCC. The significant disruption in screening cirrhotic patients for HCC has led to a delay in diagnosis.

背景和目的:目前,肝脏恶性肿瘤是全球第六常见的癌症。由于2019冠状病毒病(COVİD-19)大流行的限制,住院患者减少,尤其是疑似癌症患者的诊断和治疗延迟。通过这项研究,我们旨在调查新冠肺炎大流行是否导致肝细胞癌(HCC)数量减少或诊断延迟。方法:该研究包括新诊断的HCC患者,作为一项回顾性横断面研究,在土耳其的一个医疗中心进行。将患者分为新冠肺炎前和新冠肺炎后两年,并在肿瘤大小、生化参数、临床和人口统计学特征方面进行比较。结果:共包括63名HCC患者、46名(73%)新冠肺炎大流行前患者和17名(27%)在新冠肺炎大流行期间诊断的患者。病变的最大直径和血清甲胎蛋白水平在两组之间显示出统计学上的显著差异。新冠肺炎前时期的最大肿瘤大小为4.58±3.77 mm,而新冠肺炎时期为7.42±6.88 mm,两组之间的差异具有统计学意义(P结论:新冠肺炎大流行限制了患者接受HCC筛查计划的机会。肝硬化患者HCC筛查的显著中断导致诊断延迟。
{"title":"Effect of COVID-19 Pandemic on Hepatocellular Carcinoma Diagnosis: Results from a Single Turkey Center Study.","authors":"Gülden Bilican,&nbsp;Seçkin Özgül,&nbsp;Nergiz Ekmen,&nbsp;Kenan Moral,&nbsp;Harun Küçük,&nbsp;Serkan Dumanlı,&nbsp;Azer Abiyev,&nbsp;Tarkan Karakan,&nbsp;Murat Kekilli","doi":"10.15403/jgld-4821","DOIUrl":"https://doi.org/10.15403/jgld-4821","url":null,"abstract":"<p><strong>Background and aims: </strong>Currently malignancies of the liver are the sixth most frequently diagnosed cancers worldwide. The admission of patients to hospitals decreased due to the restriction of the Coronavirus disease 2019 (COVİD-19) pandemic, especially patients suspected with cancer were delayed in their diagnosis and treatment. With this study, we aimed to investigate whether the Covid-19 pandemic caused a decrease in the number of hepatocellular cancers (HCC) or a delay in its diagnosis.</p><p><strong>Methods: </strong>The study, which included newly diagnosed HCC patients, was conducted as a retrospective cross sectional study, in a single Turkey medical center. The patients were divided into pre-COVID-19 and post- COVID-19 two-year periods and compared in terms of tumor size, biochemical parameters, clinical and demographic features.</p><p><strong>Results: </strong>A total of 63 HCC patients, 46 (73%) patients before the COVID-19 pandemic and 17 (27%) patients diagnosed during the COVID-19 pandemic were included. Maximum diameter of lesions and serum alpha- fetoprotein levels showed a statistically significant difference between the groups. Maximum tumor size in the pre-COVID-19 period was 4.58±3.77 mm, while in the COVID-19 period was 7.42±6.88 mm, the difference between two groups being statistically significant (p<0.05). HCC in the pre-COVID-19 period were detected mostly at Barcelona Clinic for Liver Cancer (BCLC) stage A (45.7%, n=21), while in the COVID-19 period most of HCC were detected at stage B (35.3%, n=6).</p><p><strong>Conclusions: </strong>The COVID-19 pandemic limited the access of patients to screening programs for HCC. The significant disruption in screening cirrhotic patients for HCC has led to a delay in diagnosis.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"32 3","pages":"367-370"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41143934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of gastrointestinal and liver diseases : JGLD
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1